Refine by
Vedanta Medical Equipment & Supplies In In Grenada
5 equipment items found
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under cGMP conditions. It is produced under cGMP conditions from pure, clonal ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE416 is an orally administered rationally-defined bacterial consortium candidate being developed for the potential treatment of food allergy. VE416 consists of clonal human commensal bacterial strains selected for their ability to suppress allergic responses and manufactured under cGMP conditions. It is produced from pure, non-pathogenic clonal bacterial cell banks, which yield a standardized ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE707 is a preclinical discovery program for the prevention of infection and colonization recurrence of several multi-drug resistant organisms (MDROs) including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE), which are some of the most common hospital-acquired ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE800 is an orally administered rationally-defined bacterial consortium immuno-oncology candidate. VE800 consists of 11 clonal human commensal bacteria strains manufactured under cGMP conditions and selected for their ability to induce CD8+ T cells, potentiate the immune system’s attack of tumors and enhance the effects of checkpoint ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE202 is an orally administered rationally-defined bacterial consortium candidate being developed for the potential treatment of inflammatory bowel disease (IBD). VE202 consists of clonal human commensal bacteria strains selected for their ability to impact the number and activity of regulatory T cells in the gut mucosa and manufactured under cGMP ...